Trials / Conditions / Myelodysplastic Syndrome With Excess Blasts

Myelodysplastic Syndrome With Excess Blasts

16 registered clinical trials studyying Myelodysplastic Syndrome With Excess Blasts — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes W NCT03816319	National Cancer Institute (NCI)	Phase 1
Recruiting	A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS NCT06372717	Apollo Therapeutics Ltd	Phase 1
Active Not Recruiting	Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodys NCT05600894	National Cancer Institute (NCI)	Phase 2
Terminated	Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers NCT04083170	Fred Hutchinson Cancer Center	Phase 2
Active Not Recruiting	Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Ac NCT03399773	Fred Hutchinson Cancer Center	Phase 2
Recruiting	211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Recruiting	Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome NCT03383575	M.D. Anderson Cancer Center	Phase 2
Recruiting	211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782	M.D. Anderson Cancer Center	Phase 2
Recruiting	Personalized NK Cell Therapy in CBT NCT02727803	M.D. Anderson Cancer Center	Phase 2
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985	Fred Hutchinson Cancer Center	Phase 2
Active Not Recruiting	Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic S NCT01522976	National Cancer Institute (NCI)	Phase 2
Completed	Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacit NCT01168219	National Cancer Institute (NCI)	Phase 2
Recruiting	Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Tre NCT00801489	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT00392353	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission NCT00093470	National Cancer Institute (NCI)	Phase 3